fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Naltrexone HCL

All products: general benefit

Naltrexone Hydrochloride Tablets USP · DIN 02451883 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Naltrexone Hydrochloride Tablets USP · DIN 02451883 Manufacturer: Sterinova Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-05-30 · brand NALTREXONE HYDROCHLORIDE TABLETS USP · ATC N07BB04 NALTREXONE · form Tablet · route Oral · ingredients NALTREXONE HYDROCHLORIDE 50 MG · company Sterinova inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naltrexone Hydrochloride Tablets USP: Formulary list price $2.81 per unit (the source does not state the unit; exact figure $2.8075). What the ministry pays, not the patient.

Ministry pays: $2.8075 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02451883)

Source record
DIN 02451883: Naltrexone Hydrochloride Tablets USP Raw flags: sec3=Y Item: 281000003; group id 419; item number 1035; lccId None; manufacturer id STN Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $2.8075; ministry $2.8075 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02451883 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93829
Interchangeable products
Apo-Naltrexone · DIN 02444275 · $2.8075 Revia · DIN 02213826 · $2.8075
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02451883
Shortage record checked October 6, 2026
Other drugs in the same formulary class (28:10 Opiate Antagonists) and how they are covered
No products matched this class search: “28:10”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 28:08 Analgesics, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE REVIA (naltrexone hydrochloride) is indicated to provide blockade of the pharmacologic effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified, formerly opioid-dependent individuals. There are no data that demonstrate an unequivocally beneficial effect of REVIA on the rates of recidivism among detoxified formerly opioid-dependent individuals, who self administer the drug. REVIA is expected to have a therapeutic effect only when given under conditions that support continued use of the medication. REVIA is indicated in the treatment of alcohol dependence, as a component of a comprehensive psychotherapeutic or psychological alcoholism counselling program to support abstinence, and reduce the risk of relapse. The efficacy of REVIA beyond twelve weeks of treatment has not been established. https://pdf.hres.ca/dpd_pm/00060340.PDF PM date: July 16, 2020 Source product: REVIA; DIN 02213826; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.